Novo Nordisk’s Weekly Insulin Isn’t Just a Dosing Upgrade — It’s a Strategic Lifeline in a GLP-1 World
FDA approval of once-weekly insulin icodec-abae (Awiqli) gives Novo Nordisk a differentiated basal insulin, but peak sales of $1.2B...
Awiqli
FDA approval of once-weekly insulin icodec-abae (Awiqli) gives Novo Nordisk a differentiated basal insulin, but peak sales of $1.2B...